Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Connect with us

Hi, what are you looking for?

slide 3 of 2
THE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & LifestyleTHE BIZNOB – Global Business & Financial News – A Business Journal – Focus On Business Leaders, Technology – Enterpeneurship – Finance – Economy – Politics & Lifestyle

Finance

Finance

Bayer one step closer to acquiring Monsanto

Listen to the article now

There’s about to be a new monopoly in town

German pharmaceutical company Bayer launched a cash call for 6 billion euros ($7 billion) to finance the acquisition of seed and pesticide manufacturer Monsanto. The deal estimates at around $62.5 billion (!!!).

Last week, Bayer received approval from the US for the acquisition, which was one of their biggest hurdles. Although this deal will create the largest pesticide company in the world by an enormous margin, the Department of Justice did not deem the deal as violating any antitrust laws.

And although the cash call won’t be enough to secure the deal, Bayer is taking other measures to ensure it acquires the seed company. Further, they sold a good chunk of their stake in plastic manufacturer Covestro, which supplied them with 4.5 billion euros. The firm also sold assets to German chemical producer BASF for 7.6 billion euros.

According to Bayer’s executives, they are close enough to close the deal, which will supposedly close on Thursday. Moreover, they must stay true to this deadline, for Monsanto will pull out of the deal after June 14thand raise the asking price.

Forecasting their earnings based on their 2017 sales, Bayer will produce 20 billion euros worth of agricultural products. The next leading competitors, Corteva Agriscience and Syngenta, will make roughly 12.4 and 7.9 billion euros, respectively.

This acquisition has no small asking price, but clearly, the deal will show immediate returns for Bayer. The competition will have significant work to do if this deal goes through.

 

Featured image via Flickr/Conan


Comment Template

You May Also Like

Agriculture

Beef prices remain high as U.S. cattle herds decline to their lowest in 74 years. Drought, high feed costs, and strong demand drive ranchers...

Technology

U.S. antitrust regulators are investigating Big Tech’s role in the AI boom and if its business practices impede competition. The U.S. Department of Justice...

Business

Antitrust Allegations: US Accuses Apple of Smartphone Market Monopoly The United States has filed a groundbreaking lawsuit against Apple, alleging the tech giant of...

Business

Bayer has prevailed in a trial. A Californian man who claimed to have developed cancer as a result of exposure to the company’s Roundup...

Notice: The Biznob uses cookies to provide necessary website functionality, improve your experience and analyze our traffic. By using our website, you agree to our Privacy Policy and our Cookie Policy.

Ok